drugset / Trial / NCT07619365
Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer
Phase 2
Not yet recruiting
60 enrolled
Washington University School of Medicine
National Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate use of lovastatin, a drug that may lower CAV-1 levels, in order to increase HER2 expression on cells and enhance the uptake and efficacy of trastuzumab deruxtecan (T-DXd) in HER2-low and ultralow advanced metastatic breast cancer. Trastuzumab deruxtecan (T-DXd) is an FDA approved antibody drug conjugate for HER2-low and ultralow breast cancer and lovastatin is a cholesterol lowering agent.
Timeline
- Start
- 2026-08-31
- Primary completion
- 2030-08-31
- Completion
- 2031-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lovastatin | Small molecule | 20 mg | Oral |
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | 5.4 mg/kg | Intravenous |